Transcription factor ETV6 (ETV6), Bovine, ELISA Kit
- Known as:
- Transcription factor ETV6 (ETV6), Bovine, Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- H7250
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- Glory
- Gene target:
- Transcription factor ETV6 (ETV6) Bovine ELISA Kit
Related genes to: Transcription factor ETV6 (ETV6), Bovine, ELISA Kit
- Gene:
- ETV6 NIH gene
- Name:
- ETS variant 6
- Previous symbol:
- -
- Synonyms:
- TEL
- Chromosome:
- 12p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-28
- Date modifiied:
- 2019-04-23
Related products to: Transcription factor ETV6 (ETV6), Bovine, ELISA Kit
Related articles to: Transcription factor ETV6 (ETV6), Bovine, ELISA Kit
- Relapse during treatment of B-cell acute lymphoblastic leukemia (B-ALL) is a harbinger of poor outcomes. Identifying biomarkers for subsequent relapse risk which are detectable at B-ALL diagnosis remains a priority. Off-target recombination-activating gene (RAG)-mediated structural variants (SVs) generate genomic instability that drives leukemogenesis and may underlie treatment resistance. Leveraging sequencing data in 1,496 pediatric B-ALL patients enriched for relapse status (relapse n=532; non-relapse n=964), we characterized RAG-mediated SVs across B-ALL molecular subtypes and examined their association with patient characteristics and their impact on clinical outcomes. Off-target RAG-mediated SVs were overall frequent, particularly in , -like, and Ph-like B-ALL subtypes, while increasing age-at-diagnosis was positively associated with burden of off-target RAG-mediated SVs (P<.001). Off-target RAG-mediated SVs with a recombination signal sequence (RSS) at one breakpoint, a hallmark of off-target RAG activity, were significantly more frequent at diagnosis in patients who subsequently relapsed (P=.001). This association remained significant in multivariable regression analysis (per SV odds ratio [OR]:1.08, 95%CI:1.04-1.12), in minimal residual disease (MRD)-negative patients (OR:1.09, 95%CI:1.04-1.14) and across subtypes. Excluding deletions, MRD-negative patients with ≥3 off-target RAG-mediated SVs had a >3-fold risk of relapse (hazard ratio:3.47, 95% CI:1.86-6.49). RAG-mediated SVs were also associated with relapse risk in T-cell ALL patients. Off-target RAG-mediated SV burden at diagnosis is a risk factor of relapse in pediatric ALL across molecular subtypes and independent of MRD status. - Source: PubMed
Publication date: 2026/05/22
Liu TanxinLi YunqiWang CharleyClark Cassandra JAnderson NathanMarcotte ErinLieber Michael RSwaminathan SrividyaWiemels Joseph LSpector Logan GSankaran Vijay GFries Carolde Smith Adam J - While ETV6::RUNX1-positive acute lymphoblastic leukemia (ALL) is generally associated with favorable outcomes, a subset of patients experience relapse despite receiving standard therapy, underscoring the need for early biomarkers to identify high-risk subgroups. In this retrospective study of 345 consecutive pediatric patients with ETV6::RUNX1-positive ALL treated in accordance with the protocol of the Chinese Children's Leukemia Group (CCLG-ALL 2008), CD33 expression (CD33) on leukemic blasts was detected in 55.9% of patients and was significantly associated with minimal residual disease (MRD) positivity on day 15 (D15-MRD-positive) (65.2% vs. 42.0%, P < 0.001). Multivariate analysis revealed CD33 status as an independent risk factor for D15-MRD positivity (odds ratio (OR) = 2.66, 95% confidence interval (CI) 1.66-4.26). Among CD33 patients, those who were D15-MRD-positive had significantly inferior 5-year and 10-year event-free survival (EFS) relative to those who were D15-MRD-negative (5-year EFS: 91.9% ± 2.4% vs. 100%, P = 0.027; 10-year EFS: 89.2% ± 3.0% vs. 100%, P = 0.014). This prognostic association was not observed in CD33-negative patients. In conclusion, the combination of CD33 and D15-MRD-positivity may identify a distinct high-risk subgroup within ETV6::RUNX1-positive ALL. Early intervention, potentially including CD33-directed therapy, may represent a promising strategy to improve outcomes in this subgroup, although further validation is warranted. - Source: PubMed
Publication date: 2026/05/29
Zheng XuelingLuo YuxiZhang RuidongLiu XiaohangHuang PengliGao ChaoChen HuiFan JiaLin WeiYu JiaoleZhang YuanyuanQi PeijingWu YingZhao XiaoxiLi JunPeng XiaoxiaWang TianyouZheng Huyong - Secretory carcinoma (SC) is a rare salivary gland neoplasm characterized by the ETV6::NTRK3 gene fusion, and it has been recognized as a distinct entity in the World Health Organization Classification of Head and Neck Tumors since 2017. Case 1 involved a 21-year-old Japanese man who presented with a 1-year history of a slow-growing, painless mass in the right parotid gland. Ultrasonography and magnetic resonance imaging demonstrated a well-circumscribed, homogeneous tumor measuring 16x12x10 mm. The patient underwent superficial parotidectomy. Case 2 involved a 79-year-old Japanese man who noticed a mass in the right parotid region 3 weeks before presentation. Imaging studies revealed a tumor with irregular margins and heterogeneous internal features, measuring 21x16x15 mm. The patient underwent total parotidectomy with selective neck dissection. Histological examination revealed features consistent with SC in both cases. Immunohistochemically, the tumor cells were positive for S-100 protein, mammaglobin and cytokeratin 7. The diagnosis was further supported by detection of the ETV6::NTRK3 gene fusion using reverse transcription-polymerase chain reaction and Sanger sequencing. Both patients received postoperative radiotherapy at a total dose of 60 Gy. No evidence of local recurrence or distant metastasis has been observed during the follow-up period of 7 years in case 1 and 3 years in case 2. - Source: PubMed
Publication date: 2026/05/07
Hayashi MisakiBandoh NobuyukiGoto TakashiHayashi ShutoArima RyotaNakamuta KokiIsochi-Yamaguchi TomomiBaba ShogoKato YasutakaTakahara MikiTakei Hidehiro - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and genomic profiling has become increasingly vital for risk stratification. We conducted a retrospective single-center study including 96 newly diagnosed pediatric patients with ALL and mixed phenotype acute leukemia to characterize the genomic landscape using conventional and molecular cytogenetics, multiplex ligation-dependent probe amplification and targeted next-generation sequencing and to evaluate associations with treatment response and survival. Mutation co-occurrence analysis revealed a NRAS/KRAS/JAK cluster and an :: cluster characterized by relative mutational exclusivity, with additional associations between - and -CCND3 alterations. Del alterations showed a trend toward higher day-15 minimal residual disease (MRD) levels and inferior 2-year event free survival rate (EFS). Del-positive cases showed lower 2-year EFS. In contrast, :: and high hyperdiploidy were associated with favorable early response and EFS. Del did not independently influence outcome. positive cases showed higher early MRD levels despite excellent survival outcomes. NRAS/KRAS mutations were significantly associated with higher positive day-15 MRD (Wilcoxon, = 0.0067) and remained independently associated after adjustment for white blood cell count and cytogenetic subgroup. Intermediate risk (IR) and high-risk groups showed comparable 2-year EFS, indicating limited discrimination by conventional risk stratification. The IR group displayed a heterogeneous genomic profile, with NRAS/KRAS, Ph-like mutations and del among the most frequent alterations. These observations highlight the potential of integrated genomic profiling to refine risk stratification, particularly by identifying clinically relevant subgroups within the IR category. - Source: PubMed
Publication date: 2026/05/18
Stefan-Hodorogea AndreeaRadu LetitiaMarcu AndraSerbanica AndreeaBica AnaJercan CristinaMarcu AnaJardan DumitruJardan CeraselaCalugaru OndaDragomir MihaelaPopa CodrutaGheorghe AncaVihta KarinaDima SimonaColita Anca - Non-intestinal type sinonasal adenocarcinomas (non-ITACs) are rare entities with a wide range of histologic appearances. In this study we characterize the clinico-pathologic, immunohistochemical and molecular features of six cases of sinonasal adenocarcinoma with clear cell morphology, identified retrospectively in our files and occurring in 2 females and 4 males, with mean age of 62.6 years. Immunohistochemical and molecular studies including RNA sequencing, were performed. All cases showed a proliferation of epithelioid clear cells with slight to moderate atypia, arranged in variable patterns. Two cases had the typical histologic appearance and immunohistochemical profile of sinonasal renal cell-like adenocarcinoma, being formed of follicular structures and solid nests containing eosinophilic colloid-like material, with diffuse positivity for SOX10, carbonic anhydrase IX (CAIX), S100, and cytokeratin 7. One further case had a similar histologic appearance but lacked positivity for CAIX and S100. A previously unreported ETV6::YEATS4 rearrangement was detected by RNA sequencing in this case. Two adenocarcinomas showed mixed tubulo-papillary and acinar architecture with clear cell foci, including areas reminiscent of renal cell-like adenocarcinoma. Finally, one case had a tubulo-cystic appearance with clear cells and a surface component presenting ciliated, papillary and squamoid areas. This adenocarcinoma presented a MAP2K1 p.Gln56Pro; c.167 A > C mutation. Immunohistochemically, all cases were strongly positive for pancytokeratin and cytokeratin 7, SOX10 was positive in all cases tested (5/5), whereas S100 was positive in 4/6 cases and DOG1 in 1/3 cases. Notably, basal/myoepithelial markers and renal cell carcinoma markers, including CD10, PAX8 and RCC, were negative in all cases. Sinonasal adenocarcinomas with clear cell features are a heterogenous group of neoplasms in the spectrum of low-grade non-ITAC that must be differentiated from primary salivary-type sinonasal adenocarcinomas and from metastatic carcinomas. The differential diagnosis requires the support of an immunohistochemical panel, as well as molecular testing in selected cases. - Source: PubMed
Publication date: 2026/05/27
Franchi AlessandroDin Nasir Udvan den Hout MariArcovito GiorgiaDallan IacopoScarpitta RosaStoehr RobertAgaimy Abbas